Sinofn Health
Sinofn Health
The global nutraceutical and supplement market is undergoing a seismic shift. We are moving from a "generalized intake" model to "precision nutrition." As a leader in OEM manufacturing, SINOFN recognizes that success in today's market is not just about producing capsules or powders; it is about delivering bioavailable, compliant, and scientifically validated health outcomes.
Industrial Status: Industry 4.0 has arrived in supplement manufacturing. From automated extraction lines to blockchain-traceable raw material sourcing, the bar for quality has been raised. Market leaders are no longer competing on price alone, but on their ability to offer Information Gain—providing end-consumers with deeper insights into the efficacy, sourcing, and clinical backing of every gram consumed.
Moving beyond traditional solubility to enhance bioavailability of fat-soluble vitamins and peptides.
Using predictive analytics to match nutrient profiles with specific consumer demographic metabolic needs.
Transitioning to green manufacturing, reduced carbon footprints, and fully recyclable packaging solutions.
Driven by the clinical necessity of PKU (Phenylketonuria) treatment, our foundation is built on "Profit with Purpose." We do not just manufacture; we innovate to solve metabolic challenges.
Led by Dr. Zhang Ying (Chinese Academy of Sciences) and Dr. Tan Shengjie (Peking University), our research department focuses on the industrialization of special medical foods. With Hans van Dijk (Netherlands) spearheading EU-regulatory alignment, we bridge the gap between Asian manufacturing precision and Western compliance standards.
State-of-the-art Production Base
Capital Investment (RMB)
Core Proprietary Patents
Registered Trademarks Globally
Global market entry requires more than just a product; it requires a regulatory roadmap. SINOFN provides comprehensive support for:
We utilize advanced stability testing chambers to mimic various climatic conditions, ensuring our formulations (especially probiotics and sensitive enzymes) remain efficacious across global logistics chains.
Absolutely. We operate a pilot-scale prototyping system, allowing brands to test market concepts with smaller batches before committing to mass production.
